CPA
RARE icon

Capital Performance Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Capital Performance Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,934
Closed -$107K – 2078
2024
Q3 		$107K Buy
+1,934
New +$98.5K 0.03% 186

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Capital Performance Advisors's RARE Position: Q4 2024 in Review

Capital Performance Advisors sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2024, closing a stake of 1,934 shares — an estimated $107K sold.

Capital Performance Advisors first reported a position in RARE in Q3 2024 and held it in 1 quarter. The position peaked at $107K in Q3 2024. 312 funds tracked by Wall St. Rank hold RARE as of Q4 2024.

  • Capital Performance Advisors reported no remaining Ultragenyx Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1,934 Ultragenyx Pharmaceutical shares in Q4 2024, an estimated $107K.
  • Capital Performance Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Ultragenyx Pharmaceutical position peaked at $107K in Q3 2024.
  • 312 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.